Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 56, 511-514, February 1, 1996]
© 1996 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borg, A. L.
Right arrow Articles by Crevat, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borg, A. L.
Right arrow Articles by Crevat, A. D.

Impairment of Sodium Pump and Na+/H+ Antiport in Erythrocytes Isolated from Cancer Patients

André L. Borg, Philippe M. Gallice, Hervé N. Kovacic, Adriana E. Nicoara, Roger G. Favre and Aimé D. Crevat1

Biophysics Laboratory, Faculty of Pharmacy, Université d'Aix-Marseille II [A. L. B., P. M. G., H. N. K., A. D. C.], and Oncology Unit, University Hospital Timone [A. E. N., R. G. F.], 13385 Marseille Cedex 5, France

We sought to determine whether the impairment of sodium pump activity and Na+/H+ exchange reported in tumorigenic cells was specific to these cells or more general. Sodium pump activity and Na+/H+ exchange were measured in erythrocytes from 49 cancer patients and 51 healthy subjects. Cancer patients with a newly detected cancer or in relapse and without associated pathologies known to modify these sodium transporters were included in this study.

Two sodium pump statuses reflecting its physiological modulation were evidenced for healthy subjects (10.3 ± 0.2 and 19.4 ± 0.8 mW/liter of cells). In cancer patients, only one basal status lower than those of controls was observed (8.3 ± 0.5 mW/liter of cells; P < 0.001). Cooperativity of the Na+/H+ antiporter is the same in cancer patients and controls (2.58 ± 0.27 versus 2.60 ± 0.15). The intracellular pH (pHi) dependence curve of the antiporter was shifted toward more acidic values, and optimal pHi was lower in cancer patients than in controls (5.80 ± 0.03 versus 6.08 ± 0.02; P < 0.0001). The mean maximal rate and the Km of H+ for the Na+/H+ antiporter were higher: 8.4 ± 1.2 versus 4.6 ± 0.4 mmol H+/liter of cells/h (P < 0.01) and 514 ± 12 versus 322 ± 16 nM (P < 0.05), respectively.

Alterations of these Na+ transporters, therefore, were not restricted to cancerous cells. Among the alterations, the acidic shift in the pHi dependence of Na+/H+ exchange appears associated with cancer because this behavior has never been reported in other pathologies.

1 To whom requests for reprints should be addressed, at Laboratoire de Biophysique, Faculté de Pharmacie, Université D'Aix-Marseille II, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France. Phone: (33) 91-79-21-11; Fax: (33)91-80-26-12.

Received 7/18/95. Accepted 11/28/95.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.